Childhood Liver Cancer Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (09/26/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Childhood Liver Cancer

Added Vascular liver tumors as a less common histology of childhood liver cancer.

Hepatoblastoma

Added text to state that favorable response of the primary tumor to chemotherapy, defined as either a 30% decrease in tumor size by Response Evaluation Criteria In Solid Tumors or 90% or greater decrease in alpha-fetoprotein levels, predicted the resectability of the tumor; in turn, this favorable response predicted overall survival among all Childhood Hepatic tumor International Collaboration risk groups treated with neoadjuvant chemotherapy on the JPLT-2 Japanese national clinical trial (cited Hiyama et al. as reference 48 and level of evidence 2A).

Revised text to state that in patients with hepatoblastoma completely resected at initial diagnosis, aggressive surgical treatment of isolated pulmonary metastases that develop in the course of the disease, in conjunction with an overall strategy that includes appropriate chemotherapy, may make extended disease-free survival possible (cited Shi et al. as reference 94).

Vascular Liver Tumors

Added this new section.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summaryand PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Current Clinical Trials

Next section >
About This PDQ Summary